2001•Academic Journal of Second Military Medical UniversityRequires access

Anti-tumor activity of the recombinant human soluble vascular endothelinal growth inhibitor (VEGI)

Xiao Yang, Binghua Jiao, Yuping Zhu, Lou Yonghua, Lu Wang

Abstract

Objective: To detect anti tumor activity of the recombinant human soluble vascular endothelial growth inhibitor (VEGI). Methods: The recombinant human soluble VEGI was tested for its inhibition on proliferation of the established human umbilical vein endothelial cells (ECV304) and new born bovine aortic endothelial cells(BAEC).Mice bearing transplanted S180 sarcoma and mice with ascites S180 were treated with the recombinant human soluble VEGI. Results: The recombinant human soluble VEGI showed markedly inhibitory effect on the proliferation of endothelial cells and the growth of S180 sarcoma.It also prolonged the life time of mice with ascites S180. Conclusion: The recombinant human soluble VEGI may be applied for cancer therapy by anti angiogenesis. [

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Recombinant DNA, Vascular endothelial growth inhibitor, Umbilical vein, Angiogenesis inhibitor, Angiogenesis, Cancer research, Biology, Vascular endothelial growth factor